Organization (Industry)
Sanaria
ClinicalTrials.gov lists Sanaria as lead sponsor of 29 trials. It has 14 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers Sanaria: 29 lead-sponsored trials and 1 legal-entity registration.
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Malaria | 43 |
| Malaria, Falciparum | 35 |
| Inflammation | 3 |
| Parasitemia | 3 |
| Sepsis | 3 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2022 | 4 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 7 |
| 2017 | 2 |
| 2016 | 6 |
| 2015 | 2 |
| 2014 | 4 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (14)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PfSPZ-LARC2 Vaccine | Malaria, Falciparum | Phase 2 | 4 |
| PfSPZ-LARC2 Vaccine | Malaria | Phase 2 | 4 |
| Genetically attenuated PfSPZ Vaccine | Malaria, Falciparum | Phase 2 | 1 |
| Genetically attenuated PfSPZ Vaccine | Malaria | Phase 2 | 1 |
| PfSPZ Vaccine | Malaria | Phase 2 | 15 |
Showing 5 of 14 active programs.
Approved assets (1)
| Drug | Trials |
|---|---|
| 0,9% Chloride Sodium | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 70% hit target (n=10) | 40% on time (n=10) |
Journals published in (25)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Malaria journal | 5 |
| The American journal of tropical medicine and hygiene | 5 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 4 |
| Nature | 4 |
| The Lancet. Infectious diseases | 4 |
Showing 5 of 25 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 25 | 7 | 2025-12-02 |
Financing and grant events (54)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-10 | SBIR award | 1,000,000 | Reporter |
| 2025-07-18 | NIH grant | 945,493 | Reporter |
| 2025-07-18 | NIH grant | 1,012,212 | Reporter |
| 2025-07-16 | SBIR award | 995,072 | Reporter |
| 2025-06-27 | SBIR award | 999,150 | Reporter |
Showing 5 of 54 events.
Organization relationships (58)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 11 |
| Tanzania Commission for Science and Technology | Co sponsors trial with | 9 |
| Swiss Tropical and Public Health Institute | Co sponsors trial with | 7 |
| University System of Maryland | Co sponsors trial with | 5 |
| Wellcome Trust | Co sponsors trial with | 4 |
Showing 5 of 58 relationships.
Latest dated events (122)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 122 events.
Biomarker capability evidence (110)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD40LG | Trial collaborator | Named in trial inclusion criteria |
| CNMD | Trial sponsor | Named in trial inclusion criteria |
| CNMD | Trial sponsor | Named in trial inclusion criteria |
| CNMD | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 110 evidence rows.
On Scientist.com
Sanaria is listed as a research supplier in the Scientist.com network.
- Website
- www.sanaria.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Sanaria on Scientist.com
For prices, more details, or to contact Sanaria, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.